BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, Kirstein MM, Marquardt S, Rodt T. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2017;40:1559-66. [PMID: 28488104 DOI: 10.1007/s00270-017-1681-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Das A, Gabr A, O'Brian DP, Riaz A, Desai K, Thornburg B, Kallini JR, Mouli S, Lewandowski RJ, Salem R. Contemporary Systematic Review of Health-Related Quality of Life Outcomes in Locoregional Therapies for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30:1924-1933.e2. [PMID: 31685362 DOI: 10.1016/j.jvir.2019.07.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
3 Kim MS, Uhm JY. Impact of discriminant factors on the comfort-care of nurses caring for trans-arterial chemoembolisation patients. Support Care Cancer 2022. [PMID: 35710640 DOI: 10.1007/s00520-022-07221-0] [Reference Citation Analysis]
4 Hartrumpf KJ, Marquardt S, Werncke T, Murray T, Kirstein MM, Vogel A, Wacker F, Rodt T. Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. J Cancer Res Clin Oncol 2018;144:1991-9. [PMID: 30008024 DOI: 10.1007/s00432-018-2704-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wehling C, Dill MT, Olkus A, Springfeld C, Chang DH, Naumann P, Longerich T, Kratochwil C, Mehrabi A, Merle U, Pfeiffenberger J, Rupp C, Weiss KH, Mieth M. Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. J Cancer Res Clin Oncol 2021;147:2471-81. [PMID: 33537908 DOI: 10.1007/s00432-021-03528-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hinrichs JB, Wacker FK. [Locoregional and local ablative treatment options for liver tumors]. Internist (Berl) 2020;61:158-63. [PMID: 31919532 DOI: 10.1007/s00108-019-00725-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kang D, Shim S, Cho J, Lim HK. Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018. Korean J Radiol 2020;21:633-46. [PMID: 32410403 DOI: 10.3348/kjr.2019.0808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wehling C, Hornuss D, Schneider P, Springfeld C, Hoffmann K, Chang D, Naumann P, Mieth M, Longerich T, Kratochwil C, Mehrabi A, Gauss A, Weiss KH, Pfeiffenberger J. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2019;145:2761-9. [DOI: 10.1007/s00432-019-03005-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Wang TC, Zhang ZS, Xiao YD. Determination of Risk Factors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. J Pain Res 2020;13:649-56. [PMID: 32273750 DOI: 10.2147/JPR.S246197] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cao WZ, Zhou ZQ, Jiang S, Li H, Niu W, Gao P, Li GJ, Chen F. Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. Exp Ther Med 2019;18:4625-30. [PMID: 31798699 DOI: 10.3892/etm.2019.8163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Kirchner T, Marquardt S, Werncke T, Kirstein MM, Brunkhorst T, Wacker F, Vogel A, Rodt T. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:1554-61. [PMID: 30311050 DOI: 10.1007/s00261-018-1802-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
12 Grumme J, Werncke T, Meine TC, Becker LS, Kloeckner R, Maschke SK, Kirstein MM, Vogel A, Wacker FK, Meyer BC, Hinrichs JB, Rodt T. Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. Abdom Radiol (NY) 2020;45:3326-36. [PMID: 31781900 DOI: 10.1007/s00261-019-02349-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Patel AA, Woodrell C, Ufere NN, Hansen L, Tandon P, Verma M, Lai J, Pinotti R, Rakoski M; Palliative Care Education, Advocacy, and Research in Liver Disease (PEARL) Workgroup and the AASLD Public Health / Healthcare Delivery Special Interest Group (SIG). Developing Priorities for Palliative Care Research in Advanced Liver Disease: A Multidisciplinary Approach. Hepatol Commun 2021;5:1469-80. [PMID: 34510839 DOI: 10.1002/hep4.1743] [Reference Citation Analysis]
14 Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, Stål P, Rizell M. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver Int 2018;38:885-94. [PMID: 28941130 DOI: 10.1111/liv.13593] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
15 Serper M, Parikh ND, Thiele G, Ovchinsky N, Mehta S, Kuo A, Ho C, Kanwal F, Volk M, Asrani SK, Ghabril MS, Lake JR, Merriman RB, Morgan TR, Tapper EB. Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022. [PMID: 34990516 DOI: 10.1002/hep.32313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wohlleber K, Heger P, Probst P, Engel C, Diener MK, Mihaljevic AL. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies. Qual Life Res 2021;30:2429-66. [PMID: 34283381 DOI: 10.1007/s11136-021-02810-8] [Reference Citation Analysis]